Pricing Log in Create free account

Candel Therapeutics, Inc. (CADL) vs Design Therapeutics, Inc. (DSGN)

Candel Therapeutics, Inc. and Design Therapeutics, Inc. are both Biotechnology companies. Candel Therapeutics, Inc. and Design Therapeutics, Inc. are of similar size ($615.2M and $605.2M). Across the 11 metrics below, Design Therapeutics, Inc. leads on 8 and Candel Therapeutics, Inc. on 3.

Valuation

Metric CADL DSGN Biotechnology median
P/E n/m n/m 10.60
P/S 5,135.81 2,842.20 9.40
P/B 5.09 3.18 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 3,939.74 1,919.15 9.02
Earnings yield (16.28%) (11.79%) (32.88%)
Free cash flow yield (8.92%) (9.24%) (23.13%)

Profitability

Metric CADL DSGN Biotechnology median
Gross margin 0.00% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (81.84%) (36.87%) (51.96%)
Return on assets (56.37%) (34.57%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CADL DSGN Biotechnology median
Revenue growth (TTM) 0.00% — 6.76%
EPS growth (last fiscal year) 58.62% (38.64%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CADL DSGN Biotechnology median
Debt to equity 0.38 0.00 0.00
Current ratio 16.09 16.78 4.97
Net debt to EBITDA 1.53 2.68 1.01

Dividend

Metric CADL DSGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CADL DSGN Biotechnology median
Market cap 615.21m 605.16m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack